Subscribe To

Price Alert Latest News Economic Calendar News

VALN / EU Says Final Decision Yet To Be Taken On Terminating Valneva COVID-19 Vaccine Deal

The European Commission said that no final decision had been made about the possible termination of a contract with Valneva SE (NASDAQ: VALN) to supply its COVID-19 vaccine to the European Union. Earlier today, Valneva said it received a notice of intent from the Commission to. Read More

Demo Live Account See Partner Details

Content Topics

Says

Final

Decision

Taken

Terminating

Valneva

Covid

19 Covid 19

Vaccine

Stock

VALN

Posted: May 16 2022, 14:18

Author Name: Benzinga

VALN News

By GlobeNewsWire
October 11, 2023

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will pre

By GlobeNewsWire
August 31, 2023

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

Saint- Herb lain (France ) , August 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that

By Zacks Investment Research
June 21, 2023

Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?

Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi

By GlobeNewsWire
May 31, 2023

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Saint- Herb lain (France) , May 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its

By Zacks Investment Research
May 30, 2023

Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

By Seeking Alpha
May 6, 2023

Valneva SE (VALN) Q1 2023 Earnings Call Transcript

Valneva SE (NASDAQ:VALN ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - Chair

By GlobeNewsWire
March 30, 2023

Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

Saint Herblain (France), March 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will prese

By Seeking Alpha
March 29, 2023

Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future

Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine c

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.